Rheumatoid arthritis (RA) is a chronic and systemic inflammatory disease affecting 0.5-1% of the population worldwide. Interstitial lung disease (ILD) is a serious pulmonary complication of RA and it is responsible for 10-20% of mortality, with a mean survival of 5-8 years. However, nowadays there are no therapeutic recommendations for the treatment of RA-ILD. Therapeutic options for RA-ILD are complicated by the possible pulmonary toxicity of many disease modifying anti-rheumatic drugs (DMARDs) and by their unclear efficacy on pulmonary disease. Therefore, joint and lung involvement should be evaluated independently of each other for treatment purposes. On the other hand, some similarities between RA-ILD and idiopathic pulmonary fibrosis and the results of the recent INBIULD trial suggest a possible future role for antifibrotic agents. From this perspective, we review the current literature describing the pulmonary effects of drugs (immunosuppressants, conventional, biological and target synthetic DMARDs and antifibrotic agents) in patients with RA and ILD. In addition, we suggest a framework for the management of RA-ILD patients and outline a research agenda to fill the gaps in knowledge about this challenging patient cohort.

Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows / Cassone, Giulia; Manfredi, Andreina; Vacchi, Caterina; Luppi, Fabrizio; Coppi, Francesca; Salvarani, Carlo; Sebastiani, Marco. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 9:4(2020), pp. 1082-1082. [10.3390/jcm9041082]

Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows

Cassone, Giulia;Manfredi, Andreina;Vacchi, Caterina;Coppi, Francesca;Salvarani, Carlo;Sebastiani, Marco
2020-01-01

Abstract

Rheumatoid arthritis (RA) is a chronic and systemic inflammatory disease affecting 0.5-1% of the population worldwide. Interstitial lung disease (ILD) is a serious pulmonary complication of RA and it is responsible for 10-20% of mortality, with a mean survival of 5-8 years. However, nowadays there are no therapeutic recommendations for the treatment of RA-ILD. Therapeutic options for RA-ILD are complicated by the possible pulmonary toxicity of many disease modifying anti-rheumatic drugs (DMARDs) and by their unclear efficacy on pulmonary disease. Therefore, joint and lung involvement should be evaluated independently of each other for treatment purposes. On the other hand, some similarities between RA-ILD and idiopathic pulmonary fibrosis and the results of the recent INBIULD trial suggest a possible future role for antifibrotic agents. From this perspective, we review the current literature describing the pulmonary effects of drugs (immunosuppressants, conventional, biological and target synthetic DMARDs and antifibrotic agents) in patients with RA and ILD. In addition, we suggest a framework for the management of RA-ILD patients and outline a research agenda to fill the gaps in knowledge about this challenging patient cohort.
9
4
1082
1082
Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows / Cassone, Giulia; Manfredi, Andreina; Vacchi, Caterina; Luppi, Fabrizio; Coppi, Francesca; Salvarani, Carlo; Sebastiani, Marco. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 9:4(2020), pp. 1082-1082. [10.3390/jcm9041082]
Cassone, Giulia; Manfredi, Andreina; Vacchi, Caterina; Luppi, Fabrizio; Coppi, Francesca; Salvarani, Carlo; Sebastiani, Marco
File in questo prodotto:
File Dimensione Formato  
cassone 2020 JCM treatment RA-ILD.pdf

Open access

Descrizione: Main document
Tipologia: Versione pubblicata dall'editore
Dimensione 1.38 MB
Formato Adobe PDF
1.38 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1204645
Citazioni
  • ???jsp.display-item.citation.pmc??? 17
  • Scopus 45
  • ???jsp.display-item.citation.isi??? 35
social impact